trending Market Intelligence /marketintelligence/en/news-insights/trending/krWfni8nUpIwk5cwUQod2w2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

XBiotech raises $40M in public offering to fund clinical trials

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


XBiotech raises $40M in public offering to fund clinical trials

Austin, Texas-based XBiotech Inc. completed an underwritten public offering of common shares, raising about $40 million.

The company issued 4,848,485 shares at $8.25 apiece, and granted the underwriter a 30-day option to acquire up to 351,515 additional shares at the same issue price.

XBiotech will primarily use net proceeds to advance phase 2 clinical trials evaluating bermekimab to treat patients with hidradenitis suppurativa, a painful, long-term skin condition that causes infected bumps of skin filled with pus and scarring, and atopic dermatitis, or eczema — a chronic condition that makes skin thick, dry, red and itchy.

The funds will also be used for general corporate and working capital purposes.

Piper Jaffray acted as sole underwriter for the offering.